Source: UNIVERSITY OF MISSOURI submitted to
EXPRESSION PATTERNS AND REGULATORY PATHWAYS OF BOVINE TYPE 1 IFN
Sponsoring Institution
National Institute of Food and Agriculture
Project Status
TERMINATED
Funding Source
Reporting Frequency
Annual
Accession No.
0220631
Grant No.
(N/A)
Project No.
MOV-4-FF58
Proposal No.
(N/A)
Multistate No.
(N/A)
Program Code
(N/A)
Project Start Date
Oct 1, 2009
Project End Date
Sep 30, 2010
Grant Year
(N/A)
Project Director
Roberts, R. M.
Recipient Organization
UNIVERSITY OF MISSOURI
(N/A)
COLUMBIA,MO 65211
Performing Department
Veterinary Pathobiology
Non Technical Summary
Respiratory and digestive problems, which are commonly associated with viral pathogens, accounted for over 34 percent of the non-predatory death loss for cattle in 2007, constituting over a $1B loss for the cattle industry. Even more concerning, if a foreign disease outbreak occurred in the U.S., similar to the 2001 Foot and Mouth epidemic in Great Britain, revenue for the U.S. beef and dairy industries is projected to decrease by at least 20 percent and 16 percent respectively. As the first line of defense against viruses, Type I interferon (IFN) are the most promising candidates for prevention and treatment of a variety of viral diseases. Recombinant IFNA reduces the severity of clinical signs and duration of symptoms in cattle combating shipping fever. Furthermore, using IFN as a vaccine adjuvant for Foot and Mouth disease in both pigs and cattle significantly reduces the time for antibody titers to reach protective levels and reduces the clinical symptoms in stricken animals compared to untreated and vaccine-only controls. Decreasing the time to establish neutralizing antibody titers is absolutely necessary for a successful vaccination protocol for foreign disease in the U.S. While the experiments outlined in this work do not directly address foreign animal diseases, they will answer fundamental questions about the roles of bovine Type I IFN, which will help determine which IFN will be the best option to best treat and prevent specific disease outbreaks in cattle.
Animal Health Component
100%
Research Effort Categories
Basic
100%
Applied
(N/A)
Developmental
(N/A)
Classification

Knowledge Area (KA)Subject of Investigation (SOI)Field of Science (FOS)Percent
3113310109030%
3113410109030%
3124030116020%
3124010110120%
Goals / Objectives
Type I IFN are the first response to viral infection and have been used to prevent and treat viral diseases in human and veterinary medicine. Preliminary analysis of the bovine genome allowed me to identify an expansion of the IFN-omega (IFNW) and IFN-beta (IFNB) subfamilies, and to define a previously uncharacterized IFN subfamily,here termed IFN-chi (IFNX). In this proposal, we shall assess potential roles for the novel and expanded Type I IFN subfamilies in combating disease in cattle. First, we shall establish correlations between bovine pathogens and the up-regulation of members of the IFNW, IFNB, and IFNX subfamilies in cattle. Such information will provide clues as to which IFN may be the best candidates to employ, either by prophylaxis or therapeutically, to minimize disease outbreaks in livestock. Second, we shall analyze the regulation of both pro-inflammatory and anti-inflammatory cytokines by IFNX through microarray analysis. IFNX appears to be restricted to ungulates and its properties have never been characterized. Determining the regulated pathways for this unique subfamily may provide specific therapeutic options for ruminant species. Aim 3 is to identify the expression pattern of IFNX at the protein level. Collectively, this work will correlate information gained through the genomic resources to studies on the regulation of novel IFN genes, and their functional products at a molecular level in a systemic attempt to improve animal health. The long term goal is to improve animal health and, thereby, production efficiency in cattle and related ruminant species by utilizing data acquired from the International Bovine Genome Project on the Type I IFN locus.
Project Methods
In aim 1, we shall study the expression of individual IFNW, IFNB, and IFNX genes through RTPCR and, potentially, quantitive PCR in a) control tissues b) cell lines exposed to IFN-inducing agents that Revised 8/2008 2 mimic bacterial and parasitic pathogens and c) tissues from vaccinated animals in order to determine association patterns. The stimuli utilized in objective b will include bacterial double-stranded DNA (poly dA:dT), CpG-containing oligonucleotides, and lipopolysaccharide with and without zinc. These agents are expected to have unique IFN activation profiles because each stimuli induces IFN through a separate pathway in human and mouse. Samples from animals vaccinated against common bovine respiratory and gastrointestinal pathogens such as bovine respiratory synctial virus (BRSV), infectious bovine rhinotracheitis (IBR), and bovine viral diarrhea (BVD) will used for the in vivo derived samples (objective c). For aim 2, recombinant bovine IFNX and bovine IFNA will be compared for differences in induced gene expression in isolated blood leukocytes and MDBK (Madin Darby bovine kidney) cells by using microarrays. Particular attention will be paid to regulation of genes encoding pro-inflammatory and anti-inflammatory cytokines that may play a role in the innate immune response to infection and to the interferon stimulated genes considered to be important in anti-viral responses. In aim 3, the protein expression IFNX will be analyzed in a) control tissues b) cell lines exposed to the IFN-inducing agents discussed in aim 1 and c)tissues from vaccinated and diseased animals in order to determine association patterns through immuno-histochemistry. Verifying similar expression patterns between IFNX mRNA and protein or identifying discrepancies between the two will provide insights into the molecular control of IFNX.

Progress 10/01/09 to 09/30/10

Outputs
OUTPUTS: The first aim was to study the expression of individual IFNW, IFNB, and IFNX genes. In order to accomplish this goal, punch biopsies from the nose and blood samples were collected from nineteen calves immediately prior to vaccination and approximately 26 hours post-vaccination. The buffy coat was isolated from the blood samples after centrifugation. The RNA was isolated from the nose biopsies and buffy coats by following the protocol for the TriReagent kit (Sigma, St. Louis, MO, USA) and genomic DNA was removed through the Turbo DNase-free kit (Ambion, Austin, TX, USA). RNA was converted into cDNA through incubation at 50 C for 60 minutes in a mixture of 5 mM MgCl2, RT Buffer (1X), 0.5 mM DNTP mixture, 10 pM oligo dT, 10 mM DTT, Rnase Inhibitor, DEPC treated water, and Superscript III (Invitrogen, Carlsbad, CA, USA), the reverse transcriptase. Semi-quantitative PCR on paired pre-vaccination and post-vaccination samples from three calves verified dimorphic expression patterns and may help focus later expression analysis on specific IFN genes during quantitative RT-PCR. The DNase-free RNA samples were submitted to the University of Missouri DNA Core for high-throughput sequencing. At the DNA core's request, additional sample preparation to improve the high-throughput sequencing analysis is currently underway. The second aim of the study was to study differences in induced gene expression after treatment of cells lines with purified interferon-chi (IFNX). The coding regions of the two bovine IFNX genes were first subcloned into a GST-fusion bacterial expression vector (pGEX-4T-1). The fusion proteins were expressed in E. coli BL21 (DES) cells (Novagen) after induction through IPTG. After the production protocol was optimized, the bacteria were broken by means of a French press, and the soluble protein run through a glutathione-Sepharose column (Pierce) to bind GST-IFN fusion proteins. After elution, the fusion protein was be cleaved by thrombin and the mixture. Several methods to remove the GST were attempted including passing the cleaved protein over a glutiothione-sepharose column. At this time, an appropriate means to separate the GST fusion tag from the IFNX is still being determined. The final aim of the study was to study protein expression of IFNX through immunohistochemistry The IFNX-GST fusion protein from the longer IFNX variant was produced and purified as described in aim 2. A stable emulsion of fusion protein and Freud's adjuvant was injected subcutaneously on a rabbit. The rabbit received a second and third boost of antigen approximately every two weeks. Pre-immunization and post-immunization blood was collected with a 19 gauge needle through the central ear artery. The antiserum was removed from after allowing the blood to clot and clarify through centrifugation. The antiserum had high affinity for IFNX on Western blots, but also cross-reacted with other E.coli proteins from the same source that initially produced the recombinant protein. Therefore, a sepharose matrix was biotin-avidin crosslinked to E. coli cell lysate. The antiserum was passed over the crosslinked matrix twice to remove non-specific antibodies. PARTICIPANTS: Not relevant to this project. TARGET AUDIENCES: Not relevant to this project. PROJECT MODIFICATIONS: Not relevant to this project.

Impacts
This work will improve animal health and, thereby, production efficiency in cattle and related ruminant species by utilizing data acquired from our annotation of the Type I IFN (interferon) locus as part of the International Bovine Genome Project. The preliminary results from semi-quantitative RT-PCR in the gene expression study from pre and post-vaccinated calves have already indentified some Type I IFN that contribute to the innate immune system as a first response to viral infection and have been used to prevent and treat viral diseases in human and veterinary medicine. The use of high-throughput sequencing of these samples will greatly enhance our understanding in this area. Since this was only the first year of a two year project, the results from this work, particularly in regard to the second and third aim, have not all been realized.

Publications

  • Evolutionary Pressure On Multigene Type I Interferon Subfamilies Angela M Walker and R. Michael Roberts. 2010. Plant and Animal Genome Meeting January 9-13, 2010, San Diego CA; Abstract P230.